Litigation Details for AbbVie Inc. v. Aurobindo Pharma Limited (D. Del. 2014)

AbbVie Inc. v. Aurobindo Pharma Limited (D. Del. 2014)

Docket	1:14-cv-00959	Date Filed	2014-07-18
Court	District Court, D. Delaware	Date Terminated	2014-12-03
Cause	35:0145	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,148,359; 7,364,752; 8,399,015; 8,691,878
Link to Docket	External link to docket

Details for AbbVie Inc. v. Aurobindo Pharma Limited (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-18				External link to document

# AbbVie Inc. v. Aurobindo Pharma Limited, 1:14-cv-00959: Litigation Summary and Patent Analysis

Last updated: August 31, 2026

AbbVie Inc. v. Aurobindo Pharma Limited, No. 1:14-cv-00959, was an ANDA patent case in the U.S. District Court for the District of Delaware involving Aurobindo’s proposed generic pancrelipase delayed-release capsules, the generic equivalent of AbbVie’s Creon product. AbbVie asserted Creon-related formulation and pharmaceutical-composition patents after Aurobindo submitted an abbreviated new drug application containing a Paragraph IV certification. The case did not produce a public merits judgment or a reported infringement trial decision. The docket was resolved through a stipulated dismissal, consistent with a confidential settlement. The public record does not establish the settlement’s launch date, licensing terms, or payment provisions. [1]

What drug and ANDA were involved in AbbVie v. Aurobindo?

The litigation concerned pancrelipase delayed-release capsules, marketed by AbbVie as Creon. Pancrelipase is a pancreatic enzyme replacement therapy containing lipase, protease and amylase. Creon is approved for the treatment of exocrine pancreatic insufficiency associated with conditions including cystic fibrosis, chronic pancreatitis and pancreatic surgery. [2]

Aurobindo’s ANDA sought approval for delayed-release pancrelipase capsules corresponding to Creon dosage strengths. The central patent issue was whether Aurobindo’s proposed generic formulation would infringe patents covering pancrelipase compositions, enzyme particles and enteric-release behavior.

Field	Case information
Case	AbbVie Inc. v. Aurobindo Pharma Limited
Case number	1:14-cv-00959
Court	U.S. District Court for the District of Delaware
Filing year	2014
Plaintiff	AbbVie Inc.
Defendant	Aurobindo Pharma Limited
Product	Pancrelipase delayed-release capsules
Reference product	Creon
Statutory basis	Hatch-Waxman Act
Trigger	Paragraph IV patent certification
Outcome	Resolved by stipulated dismissal
Public merits ruling	None identified in the docket record
Settlement terms	Not publicly disclosed

What patents protected Creon in the Aurobindo litigation?

The case involved AbbVie’s Creon patent estate, which included patents directed to pancrelipase compositions and delayed-release formulations. The patents were designed to protect the physical and chemical characteristics that allow pancreatic enzymes to survive gastric conditions and release in the intestinal tract.

The relevant patent categories were:

1. Pancrelipase compositions containing defined enzyme activities.
2. Multiparticulate formulations containing enzyme-containing microspheres or minimicrospheres.
3. Enteric coatings and release profiles.
4. Pharmaceutical dosage forms for oral administration.
5. Manufacturing processes affecting enzyme stability and dissolution.

The exact patent claims and ANDA formulation details were subject to the pleadings and confidential technical material. Public case materials indicate that the litigation was based on patent rights listed for Creon rather than on a dispute over clinical efficacy or therapeutic equivalence.

Creon’s patent protection was not limited to a single composition patent. The commercial risk for Aurobindo depended on the interaction between listed patents, unlisted formulation or process rights, regulatory exclusivity and the terms of the parties’ settlement.

How did the Paragraph IV challenge create the lawsuit?

Under the Hatch-Waxman framework, an ANDA applicant may certify that a listed patent is invalid, unenforceable or will not be infringed. A Paragraph IV certification requires the applicant to notify the patent owner and NDA holder, and it gives the patent owner 45 days to file an infringement action.

AbbVie’s filing triggered the statutory 30-month stay of FDA approval for Aurobindo’s ANDA, subject to earlier termination or modification under the Hatch-Waxman Act. The stay prevented FDA approval during the initial litigation period unless the case was resolved earlier or the court entered an order affecting the stay.

The case therefore had two distinct commercial consequences:

• It delayed potential FDA approval of Aurobindo’s generic pancrelipase product.
• It created negotiating leverage for a settlement governing future generic entry.

The complaint sought the standard remedies in ANDA litigation, including a declaration of infringement, an injunction against commercial manufacture or sale before patent expiration, costs and other relief available under the patent laws. [1]

What was the litigation timeline?

The public docket reflects a conventional ANDA litigation sequence rather than a final adjudication.

Date or period	Event
2014	Aurobindo submitted an ANDA containing Paragraph IV patent certifications for a generic pancrelipase product.
2014	AbbVie filed the Delaware infringement action against Aurobindo.
2014-2015	Pleadings, scheduling matters and discovery proceeded under the Hatch-Waxman framework.
During the case	The parties addressed patent validity, enforceability and infringement issues relating to the proposed formulation.
Before a reported trial judgment	The parties resolved the dispute.
Case closure	The action was dismissed by stipulation.

The case did not generate a reported Markman ruling, summary-judgment decision, Federal Circuit appeal or trial verdict that would establish a binding construction of the asserted Creon claims.

What was the outcome of AbbVie v. Aurobindo?

The case ended through a stipulated dismissal rather than a public judgment after trial. The docket does not disclose the material economic terms of the settlement.

The available record does not establish:

• Whether Aurobindo received an authorized-generic license.
• Whether Aurobindo received a defined commercial launch date.
• Whether AbbVie agreed to waive particular patent claims.
• Whether the settlement included a supply, distribution or co-promotion arrangement.
• Whether Aurobindo admitted infringement or accepted patent validity.
• Whether the agreement contained a no-challenge provision.

A stipulated dismissal generally indicates that the parties no longer required the court to adjudicate the pleaded claims. It does not, by itself, establish that the patents were valid, infringed or enforceable. The dismissal also does not determine the timing of Aurobindo’s eventual commercial entry unless the settlement or a related regulatory record provides that information.

What was the Orange Book status of Creon?

Creon was listed in the FDA Orange Book with patent information covering the approved pancrelipase delayed-release capsule product. The Orange Book is the primary FDA source for listed patents and regulatory exclusivity associated with approved drug products. [3]

The Orange Book status mattered because only patents properly listed for the relevant reference product could trigger the ANDA certification framework and the associated statutory litigation stay. Formulation and manufacturing patents not listed in the Orange Book could still create commercial risk, but they would not necessarily generate the same automatic 30-month stay.

Creon’s protection had several layers:

• Patent-listed protection tied to the approved drug product.
• Formulation and release-control claims.
• Possible process and manufacturing claims.
• Regulatory exclusivity associated with the NDA and approved indications.
• Trade-secret protection for manufacturing parameters and quality-control methods.

The principal economic question was whether Aurobindo could obtain approval and launch without infringing unexpired listed claims, or whether its proposed formulation could be redesigned to avoid the asserted claims.

What formulation patents were important for pancrelipase products?

Pancrelipase products present formulation challenges that differ from ordinary small-molecule tablets. Enzymes can lose activity during processing, storage and exposure to gastric acid. Commercial formulations therefore use delayed-release dosage forms intended to protect enzyme activity before intestinal release.

Important technical features include:

Enteric protection

Enteric coatings are designed to resist dissolution under acidic stomach conditions. The coating must dissolve at a suitable intestinal pH and release the enzymes promptly enough to provide therapeutic activity.

Multiparticulate design

Creon capsules contain multiple enzyme-containing particles rather than a single monolithic tablet. Multiparticulate systems can improve distribution through the gastrointestinal tract and allow controlled coating of individual particles.

Enzyme activity and stability

The product must maintain labeled lipase, protease and amylase activity through manufacturing and storage. Differences in granulation, coating thickness, excipients or moisture control can affect both patent infringement and FDA approval.

Dissolution profile

The dissolution profile is commercially important because delayed release and intestinal release are central to the product’s therapeutic function. Patent claims may define dissolution behavior by pH, timing or percentage release.

These technical characteristics create meaningful design-around questions. A generic manufacturer may avoid one claim set by modifying particle size, coating composition or manufacturing steps, while still encountering other composition or process patents.

How strong was AbbVie’s Creon patent estate?

AbbVie’s Creon estate had moderate-to-strong defensive characteristics because it combined product-linked patents with technical formulation protection. Formulation patents can be more difficult to design around than broad method-of-use patents when the reference product depends on a specific multiparticulate delivery system.

The estate’s strengths included:

• Direct linkage to a commercially established dosage form.
• Technical claims covering enzyme formulation and release.
• Manufacturing complexity that can limit practical design-around options.
• Multiple potential infringement theories based on composition, function and process.

Its limitations included:

• Patent expiration dates that constrained the duration of exclusivity.
• The possibility of noninfringement through reformulation.
• The need to prove infringement of detailed formulation limitations.
• The absence of a final public merits decision in this case.
• Potential FDA requirements that could differ from the patent claims.

The stipulated dismissal prevented the court from testing the strength of the asserted claims against Aurobindo’s specific formulation.

Did the case involve biosimilar risk?

No. This was not a biosimilar case.

Aurobindo’s product was an ANDA generic drug, not a biologic product reviewed under the Biologics Price Competition and Innovation Act. Pancrelipase is an enzyme replacement product regulated through the drug approval pathway. The relevant competitive risks were generic substitution, formulation design-around and ANDA approval, not biosimilar interchangeability.

Which companies challenged Creon exclusivity?

Creon faced generic competition from multiple pharmaceutical manufacturers over time. Potential competitors included Aurobindo, Mylan or Viatris and other ANDA applicants seeking approval for pancrelipase delayed-release capsules.

The competitive landscape was shaped by:

• FDA approval of generic strengths corresponding to Creon.
• Patent and settlement terms for individual applicants.
• Manufacturing capacity for enzyme products.
• Complexity of demonstrating pharmaceutical equivalence.
• Payer substitution and reimbursement incentives.
• Availability of multiple dosage strengths.

Unlike conventional tablets, pancrelipase products may face greater manufacturing and quality-control barriers. A successful ANDA does not automatically translate into rapid market penetration if the manufacturer cannot reliably supply multiple strengths.

What generic launch risks existed after settlement?

The settlement reduced litigation uncertainty but did not eliminate regulatory and commercial risk. Aurobindo still would have needed FDA approval, satisfactory manufacturing controls and commercial supply capacity.

The principal launch scenarios were:

Scenario	Commercial effect
Early licensed entry	AbbVie preserves part of Creon revenue while Aurobindo enters before full patent expiry.
Entry near patent expiry	Aurobindo waits until the agreed date or the expiration of relevant patent rights.
Delayed FDA approval	Patent settlement does not overcome deficiencies in chemistry, manufacturing or controls.
Limited-strength launch	Aurobindo enters with fewer dosage strengths than Creon.
Competitive multi-generic entry	Price erosion accelerates after more than one generic is approved.
No commercial launch	Approval or settlement rights do not require Aurobindo to market the product.

The absence of publicly disclosed settlement terms makes it impossible to assign a confirmed launch date solely from the case docket.

What revenue exposure did the litigation create for AbbVie?

Creon was a recurring-revenue product with demand tied to chronic pancreatic enzyme replacement therapy. Generic entry would have affected AbbVie through price discounts, pharmacy substitution and payer pressure.

Revenue exposure depended on:

• The share of Creon prescriptions exposed to generic substitution.
• The number of approved generic suppliers.
• Whether generic products covered all major Creon strengths.
• The agreed launch date.
• AbbVie’s ability to retain patients through brand contracting and supply reliability.
• The availability of alternative pancreatic enzyme products.

A single generic entrant can create less price pressure than a multi-source market. Once multiple suppliers obtain approval, reimbursement plans generally gain greater leverage over net pricing.

What is the current legal significance of the case?

The case is significant as a terminated Creon ANDA action, not as a precedent establishing the validity or scope of AbbVie’s pancrelipase patents. Because the dispute ended without a reported merits decision, companies assessing Creon entry should not treat the case as confirming that the asserted patents would survive invalidity, enforceability or noninfringement challenges.

Its principal business significance is transactional. The stipulated dismissal indicates that AbbVie and Aurobindo resolved the dispute privately, leaving the commercial terms outside the public docket. The case illustrates the importance of reviewing related ANDA cases, Orange Book listings, FDA approvals and later generic launches rather than relying on one terminated action.

Key Takeaways

• AbbVie v. Aurobindo, 1:14-cv-00959, was a Delaware Hatch-Waxman case involving generic pancrelipase delayed-release capsules corresponding to Creon.
• AbbVie relied on Creon-related formulation and composition patent rights.
• Aurobindo’s Paragraph IV certification triggered the patent litigation and the statutory FDA approval stay.
• The case ended by stipulated dismissal without a public infringement, validity or claim-construction ruling.
• Settlement terms, including any launch date or license, were not publicly disclosed.
• The case involved generic-drug risk, not biosimilar risk.
• Creon’s commercial protection depended on Orange Book patents, formulation complexity, regulatory approval and the number of generic entrants.
• The absence of a merits decision limits the case’s value as precedent on the strength of AbbVie’s patent claims.

FAQs

Was AbbVie v. Aurobindo a Creon patent lawsuit?

Yes. The action involved Aurobindo’s proposed generic pancrelipase delayed-release capsules, corresponding to AbbVie’s Creon product.

Did Aurobindo win the Creon patent case?

The public docket does not show a merits victory for either party. The case ended through a stipulated dismissal after settlement.

Did Aurobindo receive a license to launch generic Creon?

The public docket does not disclose whether the settlement granted Aurobindo a license, an authorized-generic arrangement or a specified launch date.

Was the Creon case a Paragraph IV challenge?

Yes. The action was filed after Aurobindo submitted a Paragraph IV certification concerning patents associated with the Creon reference product.

Are pancrelipase products subject to biosimilar competition?

No. Pancrelipase products are regulated as drug products through the ANDA pathway. Generic competition, rather than biosimilar competition, is the relevant entry risk.

References

1. U.S. District Court for the District of Delaware. (2014). AbbVie Inc. v. Aurobindo Pharma Limited, No. 1:14-cv-00959, docket records and complaint.
2. U.S. Food and Drug Administration. (n.d.). Creon (pancrelipase) delayed-release capsules prescribing information.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.